1. Home
  2. ACRE vs SLN Comparison

ACRE vs SLN Comparison

Compare ACRE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Commercial Real Estate Corporation

ACRE

Ares Commercial Real Estate Corporation

HOLD

Current Price

$4.88

Market Cap

252.4M

Sector

Real Estate

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$11.95

Market Cap

300.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRE
SLN
Founded
2011
1994
Country
United States
United Kingdom
Employees
N/A
88
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.4M
300.9M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
ACRE
SLN
Price
$4.88
$11.95
Analyst Decision
Hold
Buy
Analyst Count
4
5
Target Price
$5.38
$42.60
AVG Volume (30 Days)
512.9K
497.9K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
11.58%
N/A
EPS Growth
26.17
N/A
EPS
1.35
N/A
Revenue
$54,833,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$16.28
N/A
P/E Ratio
$3.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.14
$4.19
52 Week High
$5.89
$12.31

Technical Indicators

Market Signals
Indicator
ACRE
SLN
Relative Strength Index (RSI) 57.12 60.88
Support Level $4.67 $5.87
Resistance Level $5.06 $12.19
Average True Range (ATR) 0.14 0.90
MACD 0.03 -0.10
Stochastic Oscillator 81.43 76.85

Price Performance

Historical Comparison
ACRE
SLN

About ACRE Ares Commercial Real Estate Corporation

Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: